Timothy Pearson
Chairman bei GLYCOMIMETICS, INC.
Vermögen: 73 950 $ am 31.03.2024
Profil
Mr. Timothy R.
Pearson, CPA, is an Independent Director at Korro Bio, Inc., a Chief Executive Officer at Carrick Therapeutics UK Ltd., a Chief Executive Officer at Carrick Therapeutics Ltd.
and a Chairman at GlycoMimetics, Inc. He is on the Board of Directors at Korro Bio, Inc. Mr. Pearson was previously employed as an Independent Director by Ra Pharmaceuticals, Inc., a Chief Financial & Accounting Officer, Executive VP by Tesaro, Inc., a Chief Financial Officer, Treasurer, EVP & Head-IR by Catalyst Health Solutions, Inc., a Chief Financial Officer & Executive Vice President by MedImmune LLC, a Commercial Lending Officer by Allfirst Bank (Baltimore, Maryland), a Treasury Manager by CIGNA Insurance Co. of North America (UK) Ltd., and an Assistant Treasurer by Integrated Health Services, Inc. He also served on the board at Xencor, Inc. He received his undergraduate degree from the University of Delaware, an undergraduate degree from the University of Maryland University College and a graduate degree from Loyola University Maryland, Inc..
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0,04% | 01.05.2024 | 24 650 ( 0,04% ) | 73 950 $ | 31.03.2024 |
Aktive Positionen von Timothy Pearson
| Unternehmen | Position | Beginn |
|---|---|---|
| GLYCOMIMETICS, INC. | Chairman | 17.05.2019 |
Carrick Therapeutics Ltd.
 Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Chief Executive Officer | 01.06.2019 |
Carrick Therapeutics UK Ltd.
 Carrick Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Carrick Therapeutics Ltd., Carrick Therapeutics UK Ltd. is a clinical-stage biopharmaceutical company based in Oxford, UK. Carrick Therapeutics translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, working in combination with existing oncology drugs to address unmet patient needs. The British company focuses on developing innovative therapies to improve patient outcomes in oncological therapy. The private company's therapies have potential in advanced breast, prostate, and ovarian cancers, with further potential in pancreatic and Ewing's sarcoma. Timothy R. Pearson has been the CEO of the company since 2019. | Chief Executive Officer | 01.07.2019 |
Ehemalige bekannte Positionen von Timothy Pearson
| Unternehmen | Position | Ende |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Director/Board Member | 02.04.2020 |
| TESARO INC | Director of Finance/CFO | 01.02.2019 |
Catalyst Health Solutions, Inc.
 Catalyst Health Solutions, Inc. Internet Software/ServicesTechnology Services Catalyst Health Solutions, Inc. was provided pharmacy benefit management services. The company was founded in 1999 and was headquartered in Rockville, MD. | Director of Finance/CFO | 02.07.2012 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Director of Finance/CFO | 01.08.2011 |
| CIGNA Insurance Co. of North America (UK) Ltd. | Corporate Officer/Principal | - |
Ausbildung von Timothy Pearson
| Loyola University Maryland, Inc. | Graduate Degree |
| University of Delaware | Undergraduate Degree |
| University of Maryland University College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XENCOR, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Integrated Health Services, Inc.
 Integrated Health Services, Inc. Hospital/Nursing ManagementHealth Services Integrated Health Services, Inc. provides post-acute healthcare services. Its Post-acute care is the provision of a continuum of care to patients following discharge from an acute care hospital. Its post-acute care services and products include inpatient services, home respiratory care & durable medical equipment, diagnostic services and lithotripsy which is a non-invasive technique that uses shockwaves to disintegrate kidney stones primarily on an outpatient basis. The company's post-acute care network is designed to address the cost containment measures implemented by private insurers & managed care organizations and limitations on government reimbursement of hospital costs that have resulted in the discharge from hospitals of many patients who continue to require medical and rehabilitative care. | Health Services |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Catalyst Health Solutions, Inc.
Catalyst Health Solutions, Inc. Internet Software/ServicesTechnology Services Catalyst Health Solutions, Inc. was provided pharmacy benefit management services. The company was founded in 1999 and was headquartered in Rockville, MD. | Technology Services |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
| Allfirst Bank (Baltimore, Maryland) | Finance |
| CIGNA Insurance Co. of North America (UK) Ltd. | |
Carrick Therapeutics Ltd.
Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Health Technology |
Carrick Therapeutics UK Ltd.
Carrick Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Carrick Therapeutics Ltd., Carrick Therapeutics UK Ltd. is a clinical-stage biopharmaceutical company based in Oxford, UK. Carrick Therapeutics translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, working in combination with existing oncology drugs to address unmet patient needs. The British company focuses on developing innovative therapies to improve patient outcomes in oncological therapy. The private company's therapies have potential in advanced breast, prostate, and ovarian cancers, with further potential in pancreatic and Ewing's sarcoma. Timothy R. Pearson has been the CEO of the company since 2019. | Commercial Services |
